• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于血液的循环微生物宏基因组panel 用于食管腺癌的早期诊断和预后评估。

A blood-based circulating microbial metagenomic panel for early diagnosis and prognosis of oesophageal adenocarcinoma.

机构信息

Allegheny Health Network Cancer Institute, Allegheny Health Network, Pittsburgh, PA, USA.

Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute of City of Hope, Monrovia, CA, USA.

出版信息

Br J Cancer. 2022 Nov;127(11):2016-2024. doi: 10.1038/s41416-022-01974-5. Epub 2022 Sep 12.

DOI:10.1038/s41416-022-01974-5
PMID:36097175
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9681745/
Abstract

BACKGROUND

Emerging evidence indicates the potential clinical significance of specific microbial signatures as diagnostic and prognostic biomarkers, in multiple cancers. However, to date, no studies have systematically interrogated circulating metagenome profiling in oesophageal adenocarcinoma (EAC) patients, particularly as novel non-invasive, early detection, surveillance and prognostic classifiers.

METHODS

Metagenome sequencing was performed on 81 serum specimens collected across EAC spectrum, with sequencing reads classified using Bracken and MetaPhlAn3. Followed by the Linear Discriminant Analysis effect size (LEfSe) method to identify microbial profiles between groups. Logistic regression and Kaplan-Meier analyses were used to build classifiers.

RESULTS

A significant loss of alpha and beta diversity was identified in serum specimens from EAC patients. We observed a shift in microbial taxa between each group-at the phylum, genus, and species level-with Lactobacillus sakei as the most prominent species in gastroesophageal reflux (GERD) vs other patient groups. Interestingly, LEfSe analysis identified a complete loss of Lactobacillus (L. Sakei and L. Curvatus), Collinsella stercoris and Bacteroides stercoris but conversely a significant increase in Escherichia coli in patients with EAC. Finally, we developed a metagenome panel that discriminated EAC from GERD patients with an AUC value of 0.89 (95% CI: 0.78-0.95; P < 0.001) and this panel in conjunction with the TNM stage was a robust predictor of overall survival (≥24 months; AUC = 0.84 (95% CI: 0.66-0.92; P = 0.006)).

CONCLUSION

This study firstly describes unique blood-based microbial profiles in patients across EAC carcinogenesis, that are further utilised to establish a novel circulating diagnostic and prognostic metagenomic signature for EAC.

TRANSLATIONAL RELEVANCE

Accumulating data indicates the clinical relevance of specific microbial signatures as diagnostic and prognostic biomarkers, in multiple cancers. However, to date, no studies have systematically interrogated circulating metagenome profiling in patients with oesophageal adenocarcinoma (EAC). Herein, we performed metagenome sequencing in serum specimens from EAC patients 81 collected across EAC spectrum and observed a significant loss of alpha and beta diversity, with a shift in microbial taxa between each group-at the phylum, genus, and species level-with Lactobacillus sakei as the most prominent species in gastroesophageal reflux (GERD) vs other patient groups. Interestingly, LEfSe analysis identified a complete loss of Lactobacillus (L. Sakei and L. Curvatus), Collinsella stercoris and Bacteroides stercoris but conversely a significant increase in Escherichia coli in patients with EAC. Finally, we developed a metagenome panel that discriminated EAC from GERD patients with an AUC value of 0.89 and this panel, in conjunction with the TNM stage, was a robust predictor of overall survival. This study for the first time describes unique blood-based microbial profiles in patients across EAC carcinogenesis, that are further utilised to establish a novel circulating diagnostic and prognostic metagenomic signature for EAC.

摘要

背景

越来越多的证据表明,特定微生物特征作为诊断和预后生物标志物,在多种癌症中具有潜在的临床意义。然而,迄今为止,尚无研究系统地研究食管腺癌(EAC)患者的循环宏基因组分析,特别是作为新型非侵入性、早期检测、监测和预后分类器。

方法

对 81 份来自 EAC 谱的血清标本进行宏基因组测序,使用 Bracken 和 MetaPhlAn3 对测序reads 进行分类。然后使用线性判别分析效应大小(LEfSe)方法来识别组间的微生物特征。使用逻辑回归和 Kaplan-Meier 分析来构建分类器。

结果

EAC 患者的血清标本中发现明显的α和β多样性丧失。我们观察到每个组之间的微生物分类群发生了变化-在门、属和种水平上-胃食管反流病(GERD)与其他患者组相比,乳杆菌属最显著。有趣的是,LEfSe 分析发现 EAC 患者中乳杆菌属(L. sakei 和 L. curvatus)、柯林斯氏菌属和拟杆菌属完全丧失,但大肠杆菌的数量显著增加。最后,我们开发了一个宏基因组面板,能够区分 EAC 与 GERD 患者,AUC 值为 0.89(95%CI:0.78-0.95;P<0.001),并且该面板与 TNM 分期相结合是总体生存的有力预测因子(≥24 个月;AUC=0.84(95%CI:0.66-0.92;P=0.006))。

结论

本研究首次描述了 EAC 发生过程中患者血液中独特的微生物特征,并进一步利用这些特征建立了一种新型的用于 EAC 的循环诊断和预后宏基因组特征。

翻译后注释

  • “EAC”:即 esophageal adenocarcinoma,食管腺癌。

  • “GERD”:即 gastroesophageal reflux,胃食管反流。

  • “AUC”:Area Under the Curve 的缩写,即曲线下面积。

相似文献

1
A blood-based circulating microbial metagenomic panel for early diagnosis and prognosis of oesophageal adenocarcinoma.基于血液的循环微生物宏基因组panel 用于食管腺癌的早期诊断和预后评估。
Br J Cancer. 2022 Nov;127(11):2016-2024. doi: 10.1038/s41416-022-01974-5. Epub 2022 Sep 12.
2
Differential MicroRNA Signatures in the Pathogenesis of Barrett's Esophagus.巴雷特食管发病机制中的差异 microRNA 特征。
Clin Transl Gastroenterol. 2020 Jan;11(1):e00125. doi: 10.14309/ctg.0000000000000125.
3
Association of MDM2 T309G and p53 Arg72Pro polymorphisms and gastroesophageal reflux disease with survival in esophageal adenocarcinoma.MDM2 T309G 和 p53 Arg72Pro 多态性与胃食管反流病对食管腺癌患者生存的影响。
J Gastroenterol Hepatol. 2013 Sep;28(9):1482-8. doi: 10.1111/jgh.12286.
4
Epidermal growth factor A61G gene polymorphism, gastroesophageal reflux disease and esophageal adenocarcinoma risk.表皮生长因子A61G基因多态性、胃食管反流病与食管腺癌风险
Carcinogenesis. 2009 Aug;30(8):1363-7. doi: 10.1093/carcin/bgp126. Epub 2009 Jun 11.
5
Laryngopharyngeal reflux symptoms better predict the presence of esophageal adenocarcinoma than typical gastroesophageal reflux symptoms.与典型的胃食管反流症状相比,喉咽反流症状能更好地预测食管腺癌的存在。
Ann Surg. 2004 Jun;239(6):849-56; discussion 856-8. doi: 10.1097/01.sla.0000128303.05898.ee.
6
Endoscopy for gastroesophageal reflux disease and survival in esophageal adenocarcinoma.内镜检查用于胃食管反流病和食管腺癌的生存情况。
Int J Cancer. 2020 Jul 1;147(1):93-99. doi: 10.1002/ijc.32721. Epub 2019 Oct 18.
7
Single nucleotide polymorphisms in the matrix metalloproteinase gene family and the frequency and duration of gastroesophageal reflux disease influence the risk of esophageal adenocarcinoma.基质金属蛋白酶基因家族的单核苷酸多态性和胃食管反流病的频率及持续时间影响食管腺癌的风险。
Int J Cancer. 2012 Dec 1;131(11):2478-86. doi: 10.1002/ijc.27541. Epub 2012 Apr 24.
8
Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome.通过肿瘤转录组分析鉴定出的食管腺癌预后生物标志物。
PLoS One. 2010 Nov 30;5(11):e15074. doi: 10.1371/journal.pone.0015074.
9
Barrett's Metaplasia Progression towards Esophageal Adenocarcinoma: An Attempt to Select a Panel of Molecular Sensors and to Reflect Clinical Alterations by Experimental Models.巴雷特食管化生向食管腺癌的进展:尝试选择一组分子传感器并通过实验模型反映临床变化。
Int J Mol Sci. 2022 Mar 18;23(6):3312. doi: 10.3390/ijms23063312.
10
Gastroesophageal reflux disease, proton-pump inhibitor use and Barrett's esophagus in esophageal adenocarcinoma: Trends revisited.胃食管反流病、质子泵抑制剂使用与食管腺癌中的 Barrett 食管:重新审视趋势。
Surgery. 2013 Oct;154(4):856-64; discussion 864-6. doi: 10.1016/j.surg.2013.07.020.

引用本文的文献

1
Preparation of robust synthetic control samples and their use in a metatranscriptomic clinical test.稳健的合成对照样本的制备及其在宏转录组临床检测中的应用。
Sci Rep. 2025 Mar 24;15(1):10101. doi: 10.1038/s41598-025-95020-y.
2
Distinctive circulating microbial metagenomic signatures in the plasma of patients with lung cancer and their potential value as molecular biomarkers.肺癌患者血浆中独特的循环微生物宏基因组特征及其作为分子生物标志物的潜在价值。
J Transl Med. 2025 Feb 14;23(1):186. doi: 10.1186/s12967-025-06209-8.
3
Shotgun Metagenomics Reveals as a Fecal Biomarker Depleted in Late-Stage Hepatocellular Carcinoma.鸟枪法宏基因组学揭示了一种在晚期肝细胞癌中减少的粪便生物标志物。
Gastro Hep Adv. 2024 Aug 30;4(1):100539. doi: 10.1016/j.gastha.2024.07.020. eCollection 2025.
4
Circulating Cell-Free Microbial DNA Signatures and Plasma Soluble CD14 Level Are Associated with Clinical Outcomes of Anti-PD-1 Therapy in Advanced Melanoma Patients.循环游离微生物DNA特征和血浆可溶性CD14水平与晚期黑色素瘤患者抗PD-1治疗的临床结局相关。
Int J Mol Sci. 2024 Dec 3;25(23):12982. doi: 10.3390/ijms252312982.
5
Circulating microbiome DNA as biomarkers for early diagnosis and recurrence of lung cancer.循环微生物组 DNA 作为肺癌早期诊断和复发的生物标志物。
Cell Rep Med. 2024 Apr 16;5(4):101499. doi: 10.1016/j.xcrm.2024.101499. Epub 2024 Apr 5.
6
Distinct compositions and functions of circulating microbial DNA in the peripheral blood compared to fecal microbial DNA in healthy individuals.与健康个体的粪便微生物 DNA 相比,外周血循环微生物 DNA 的组成和功能存在明显差异。
mSystems. 2024 Mar 19;9(3):e0000824. doi: 10.1128/msystems.00008-24. Epub 2024 Mar 1.
7
Leveraging circulating microbial DNA for early cancer detection.利用循环微生物 DNA 进行早期癌症检测。
Trends Cancer. 2023 Nov;9(11):879-882. doi: 10.1016/j.trecan.2023.08.001. Epub 2023 Sep 1.
8
The Local Microbiome in Esophageal Cancer and Treatment Response: A Review of Emerging Data and Future Directions.食管癌中的局部微生物群与治疗反应:新兴数据与未来方向综述
Cancers (Basel). 2023 Jul 10;15(14):3562. doi: 10.3390/cancers15143562.
9
Association between Gut Microbiota and Digestive System Cancers: A Bidirectional Two-Sample Mendelian Randomization Study.肠道微生物群与消化系统癌症的关联:一项双向二样本孟德尔随机化研究。
Nutrients. 2023 Jun 28;15(13):2937. doi: 10.3390/nu15132937.

本文引用的文献

1
Immunomodulatory properties of CNF1 toxin from : implications for colorectal carcinogenesis.来自的CNF1毒素的免疫调节特性:对结直肠癌发生的影响
Am J Cancer Res. 2022 Feb 15;12(2):651-660. eCollection 2022.
2
Microbiome genomics for cancer prediction.用于癌症预测的微生物组基因组学。
Nat Cancer. 2020 Apr;1(4):379-381. doi: 10.1038/s43018-020-0059-x.
3
The Role of Microbiota in Gastrointestinal Cancer and Cancer Treatment: Chance or Curse?肠道菌群在胃肠道癌症和癌症治疗中的作用:是机会还是诅咒?
Cell Mol Gastroenterol Hepatol. 2022;13(3):857-874. doi: 10.1016/j.jcmgh.2021.08.013. Epub 2021 Sep 8.
4
The Role of Microbiota in the Pathogenesis of Esophageal Adenocarcinoma.微生物群在食管腺癌发病机制中的作用
Biology (Basel). 2021 Jul 22;10(8):697. doi: 10.3390/biology10080697.
5
Detection of cell-free microbial DNA using a contaminant-controlled analysis framework.使用受污染控制分析框架检测无细胞微生物 DNA。
Genome Biol. 2021 Jun 23;22(1):187. doi: 10.1186/s13059-021-02401-3.
6
Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with bioBakery 3.利用 bioBakery 3 整合具有分类学、功能和菌株水平特征的多样化微生物群落。
Elife. 2021 May 4;10:e65088. doi: 10.7554/eLife.65088.
7
Immunostimulatory Effects of Live K040706 on the CYP-Induced Immunosuppression Mouse Model.活 K040706 对 CYP 诱导免疫抑制小鼠模型的免疫刺激作用。
Nutrients. 2020 Nov 22;12(11):3573. doi: 10.3390/nu12113573.
8
Alterations of circulating bacterial DNA in colorectal cancer and adenoma: A proof-of-concept study.结直肠癌和腺瘤患者循环细菌 DNA 的改变:概念验证研究。
Cancer Lett. 2021 Feb 28;499:201-208. doi: 10.1016/j.canlet.2020.11.030. Epub 2020 Nov 27.
9
EphA5 Silencing Increases the Radiosensitivity of ESCC Cells Through ATM-Dependent Pathway.EphA5基因沉默通过ATM依赖途径增加食管鳞癌细胞的放射敏感性。
Cancer Manag Res. 2020 Oct 2;12:9539-9549. doi: 10.2147/CMAR.S261182. eCollection 2020.
10
Mucosa-Associated Microbiota in Barrett's Esophagus, Dysplasia, and Esophageal Adenocarcinoma Differ Similarly Compared With Healthy Controls.巴雷特食管、异型增生和食管腺癌的黏膜相关微生物群与健康对照者相似。
Clin Transl Gastroenterol. 2020 Aug;11(8):e00199. doi: 10.14309/ctg.0000000000000199.